Annual FCF
-$31.91 M
+$3.18 M+9.06%
December 31, 2022
Summary
- As of February 20, 2025, ELOX annual free cash flow is -$31.91 million, with the most recent change of +$3.18 million (+9.06%) on December 31, 2022.
- During the last 3 years, ELOX annual FCF has risen by +$7.52 million (+19.07%).
Performance
ELOX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$3.45 M
-$1.38 M-66.99%
September 30, 2023
Summary
- As of February 20, 2025, ELOX quarterly free cash flow is -$3.45 million, with the most recent change of -$1.38 million (-66.99%) on September 30, 2023.
- Over the past year, ELOX quarterly FCF has increased by +$3.54 million (+50.67%).
- ELOX quarterly FCF is now -4487.77% below its all-time high of -$75.20 thousand, reached on December 31, 2001.
Performance
ELOX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$17.99 M
+$3.54 M+16.46%
September 30, 2023
Summary
- As of February 20, 2025, ELOX TTM free cash flow is -$17.99 million, with the most recent change of +$3.54 million (+16.46%) on September 30, 2023.
- Over the past year, ELOX TTM FCF has increased by +$18.21 million (+50.30%).
- ELOX TTM FCF is now -4099.58% below its all-time high of -$428.40 thousand, reached on September 30, 2000.
Performance
ELOX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ELOX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +9.1% | +50.7% | +50.3% |
| 3 y3 years | +19.1% | +34.4% | +45.1% |
| 5 y5 years | -97.3% | +62.3% | +54.4% |
ELOX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +9.1% | -67.0% | +65.3% | at high | +51.3% |
| 5 y | 5-year | -13.3% | +19.1% | -67.0% | +71.1% | at high | +57.3% |
| alltime | all time | <-9999.0% | +19.1% | -4487.8% | +71.1% | -4099.6% | +57.3% |
Eloxx Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$3.45 M(+67.0%) | -$17.99 M(-16.5%) |
| Jun 2023 | - | -$2.07 M(-69.7%) | -$21.54 M(-26.3%) |
| Mar 2023 | - | -$6.81 M(+20.4%) | -$29.22 M(-8.4%) |
| Dec 2022 | -$31.91 M(-9.1%) | -$5.66 M(-19.1%) | -$31.91 M(-11.9%) |
| Sep 2022 | - | -$6.99 M(-28.3%) | -$36.20 M(-1.8%) |
| Jun 2022 | - | -$9.75 M(+2.7%) | -$36.86 M(-0.1%) |
| Mar 2022 | - | -$9.50 M(-4.5%) | -$36.91 M(+5.2%) |
| Dec 2021 | -$35.09 M(+24.6%) | -$9.95 M(+30.0%) | -$35.09 M(+17.7%) |
| Sep 2021 | - | -$7.66 M(-21.8%) | -$29.81 M(+8.8%) |
| Jun 2021 | - | -$9.80 M(+27.5%) | -$27.41 M(+14.5%) |
| Mar 2021 | - | -$7.68 M(+64.6%) | -$23.93 M(-15.1%) |
| Dec 2020 | -$28.17 M(-28.6%) | -$4.67 M(-11.2%) | -$28.17 M(-14.0%) |
| Sep 2020 | - | -$5.26 M(-16.8%) | -$32.76 M(-15.7%) |
| Jun 2020 | - | -$6.32 M(-47.0%) | -$38.84 M(-7.8%) |
| Mar 2020 | - | -$11.92 M(+28.8%) | -$42.15 M(+6.9%) |
| Dec 2019 | -$39.43 M(+24.8%) | -$9.26 M(-18.4%) | -$39.43 M(+0.2%) |
| Sep 2019 | - | -$11.35 M(+17.9%) | -$39.34 M(+8.9%) |
| Jun 2019 | - | -$9.62 M(+4.6%) | -$36.12 M(+3.0%) |
| Mar 2019 | - | -$9.20 M(+0.5%) | -$35.05 M(+10.9%) |
| Dec 2018 | -$31.60 M(+95.4%) | -$9.16 M(+12.7%) | -$31.60 M(+40.8%) |
| Sep 2018 | - | -$8.13 M(-5.0%) | -$22.44 M(+50.8%) |
| Jun 2018 | - | -$8.55 M(+48.7%) | -$14.88 M(+117.7%) |
| Mar 2018 | - | -$5.75 M(+900.2%) | -$6.84 M(+254.5%) |
| Dec 2017 | -$16.17 M(+739.0%) | - | - |
| Sep 2017 | - | -$575.30 K(+13.1%) | -$1.93 M(+0.1%) |
| Jun 2017 | - | -$508.80 K(+25.0%) | -$1.93 M(-9.7%) |
| Jun 2017 | -$1.93 M(-47.6%) | - | - |
| Mar 2017 | - | -$407.20 K(-7.0%) | -$2.13 M(-16.9%) |
| Dec 2016 | - | -$437.90 K(-23.7%) | -$2.57 M(-17.7%) |
| Sep 2016 | - | -$573.70 K(-19.7%) | -$3.12 M(-15.2%) |
| Jun 2016 | -$3.68 M(-51.7%) | -$714.80 K(-15.0%) | -$3.68 M(-25.3%) |
| Mar 2016 | - | -$841.00 K(-14.9%) | -$4.92 M(-13.9%) |
| Dec 2015 | - | -$988.30 K(-12.7%) | -$5.72 M(-11.5%) |
| Sep 2015 | - | -$1.13 M(-42.3%) | -$6.46 M(-15.0%) |
| Jun 2015 | -$7.60 M(+38.4%) | -$1.96 M(+19.9%) | -$7.60 M(+7.4%) |
| Mar 2015 | - | -$1.64 M(-5.3%) | -$7.08 M(-1.1%) |
| Dec 2014 | - | -$1.73 M(-23.9%) | -$7.15 M(+2.8%) |
| Sep 2014 | - | -$2.27 M(+58.3%) | -$6.96 M(+26.6%) |
| Jun 2014 | -$5.50 M(+24.0%) | -$1.44 M(-16.2%) | -$5.50 M(+6.9%) |
| Mar 2014 | - | -$1.71 M(+11.9%) | -$5.14 M(-3.4%) |
| Dec 2013 | - | -$1.53 M(+88.4%) | -$5.32 M(+19.3%) |
| Sep 2013 | - | -$813.40 K(-24.7%) | -$4.46 M(+0.7%) |
| Jun 2013 | -$4.43 M(-8.4%) | -$1.08 M(-43.0%) | -$4.43 M(-2.9%) |
| Mar 2013 | - | -$1.90 M(+182.2%) | -$4.57 M(+21.4%) |
| Dec 2012 | - | -$671.90 K(-14.2%) | -$3.76 M(-14.5%) |
| Sep 2012 | - | -$783.50 K(-35.5%) | -$4.40 M(-9.0%) |
| Jun 2012 | -$4.84 M | -$1.22 M(+11.3%) | -$4.84 M(-1.2%) |
| Mar 2012 | - | -$1.09 M(-16.8%) | -$4.89 M(-7.1%) |
| Dec 2011 | - | -$1.31 M(+7.6%) | -$5.27 M(-5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2011 | - | -$1.22 M(-4.2%) | -$5.56 M(-8.5%) |
| Jun 2011 | -$6.08 M(+9.5%) | -$1.27 M(-13.2%) | -$6.08 M(-19.7%) |
| Mar 2011 | - | -$1.47 M(-8.5%) | -$7.56 M(+10.5%) |
| Dec 2010 | - | -$1.60 M(-7.6%) | -$6.85 M(+13.2%) |
| Sep 2010 | - | -$1.74 M(-37.1%) | -$6.05 M(+8.9%) |
| Jun 2010 | -$5.55 M(+17.0%) | -$2.76 M(+268.1%) | -$5.55 M(+37.4%) |
| Mar 2010 | - | -$749.70 K(-6.8%) | -$4.04 M(-4.5%) |
| Dec 2009 | - | -$804.00 K(-35.1%) | -$4.23 M(-10.3%) |
| Sep 2009 | - | -$1.24 M(-0.6%) | -$4.72 M(-0.7%) |
| Jun 2009 | -$4.75 M(+49.8%) | -$1.25 M(+32.9%) | -$4.75 M(+3.9%) |
| Mar 2009 | - | -$938.20 K(-27.4%) | -$4.57 M(-2.2%) |
| Dec 2008 | - | -$1.29 M(+1.7%) | -$4.67 M(+10.4%) |
| Sep 2008 | - | -$1.27 M(+18.8%) | -$4.23 M(+33.5%) |
| Jun 2008 | -$3.17 M(+25.3%) | -$1.07 M(+2.8%) | -$3.17 M(+19.3%) |
| Mar 2008 | - | -$1.04 M(+21.9%) | -$2.66 M(+11.5%) |
| Dec 2007 | - | -$853.20 K(+311.6%) | -$2.38 M(+2.5%) |
| Sep 2007 | - | -$207.30 K(-62.7%) | -$2.32 M(-8.1%) |
| Jun 2007 | -$2.53 M(-23.9%) | -$556.20 K(-27.3%) | -$2.53 M(-23.8%) |
| Mar 2007 | - | -$765.30 K(-3.7%) | -$3.32 M(-2.2%) |
| Dec 2006 | - | -$794.80 K(+92.4%) | -$3.39 M(+8.6%) |
| Sep 2006 | - | -$413.20 K(-69.3%) | -$3.13 M(-5.9%) |
| Jun 2006 | -$3.32 M(+25.2%) | -$1.35 M(+60.0%) | -$3.32 M(+22.1%) |
| Mar 2006 | - | -$841.10 K(+59.6%) | -$2.72 M(-9.1%) |
| Dec 2005 | - | -$527.00 K(-13.4%) | -$2.99 M(+8.5%) |
| Sep 2005 | - | -$608.80 K(-18.1%) | -$2.76 M(+4.0%) |
| Jun 2005 | -$2.65 M(+18.3%) | -$743.20 K(-33.2%) | -$2.65 M(-8.0%) |
| Mar 2005 | - | -$1.11 M(+278.9%) | -$2.89 M(+32.9%) |
| Dec 2004 | - | -$293.80 K(-41.6%) | -$2.17 M(-6.2%) |
| Sep 2004 | - | -$503.50 K(-48.4%) | -$2.32 M(+3.2%) |
| Jun 2004 | -$2.24 M(+10.2%) | -$974.90 K(+144.1%) | -$2.24 M(+20.8%) |
| Mar 2004 | - | -$399.40 K(-8.8%) | -$1.86 M(-0.1%) |
| Dec 2003 | - | -$438.00 K(+1.5%) | -$1.86 M(-5.0%) |
| Sep 2003 | - | -$431.40 K(-26.6%) | -$1.96 M(-3.9%) |
| Jun 2003 | -$2.04 M(+52.2%) | -$588.00 K(+46.2%) | -$2.04 M(+13.3%) |
| Mar 2003 | - | -$402.10 K(-24.9%) | -$1.80 M(-8.8%) |
| Dec 2002 | - | -$535.30 K(+4.9%) | -$1.97 M(+30.4%) |
| Sep 2002 | - | -$510.40 K(+46.0%) | -$1.51 M(+13.0%) |
| Jun 2002 | -$1.34 M(-11.4%) | -$349.50 K(-39.3%) | -$1.34 M(+4.3%) |
| Mar 2002 | - | -$576.20 K(+666.2%) | -$1.28 M(+24.0%) |
| Dec 2001 | - | -$75.20 K(-77.7%) | -$1.03 M(-27.1%) |
| Sep 2001 | - | -$336.90 K(+14.5%) | -$1.42 M(-6.1%) |
| Jun 2001 | -$1.51 M(-17.0%) | -$294.20 K(-10.3%) | -$1.51 M(+24.2%) |
| Mar 2001 | - | -$327.90 K(-28.7%) | -$1.22 M(+36.9%) |
| Dec 2000 | - | -$459.80 K(+7.3%) | -$888.20 K(+107.3%) |
| Sep 2000 | - | -$428.40 K | -$428.40 K |
| Jun 2000 | -$1.82 M(+66.6%) | - | - |
| Jun 1999 | -$1.09 M(<-9900.0%) | - | - |
| Jun 1998 | $0.00(0.0%) | - | - |
| Jun 1997 | $0.00 | - | - |
FAQ
- What is Eloxx Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals annual FCF year-on-year change?
- What is Eloxx Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals quarterly FCF year-on-year change?
- What is Eloxx Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals TTM FCF year-on-year change?
What is Eloxx Pharmaceuticals annual free cash flow?
The current annual FCF of ELOX is -$31.91 M
What is the all time high annual FCF for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high annual free cash flow is $0.00
What is Eloxx Pharmaceuticals annual FCF year-on-year change?
Over the past year, ELOX annual free cash flow has changed by +$3.18 M (+9.06%)
What is Eloxx Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of ELOX is -$3.45 M
What is the all time high quarterly FCF for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high quarterly free cash flow is -$75.20 K
What is Eloxx Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, ELOX quarterly free cash flow has changed by +$3.54 M (+50.67%)
What is Eloxx Pharmaceuticals TTM free cash flow?
The current TTM FCF of ELOX is -$17.99 M
What is the all time high TTM FCF for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high TTM free cash flow is -$428.40 K
What is Eloxx Pharmaceuticals TTM FCF year-on-year change?
Over the past year, ELOX TTM free cash flow has changed by +$18.21 M (+50.30%)